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Abstract
Background—Understanding the potential for vaccination to change cytomegalovirus (CMV) 
epidemiology is important for developing CMV vaccines and designing clinical trials.
Methods—We constructed a deterministic, age-specific and time-dependent mathematical model 
of pathogen transmission, parameterized using CMV seroprevalence from the United States and 
Brazil, to predict the impact of vaccination on congenital CMV infection.
Findings—Concurrent vaccination of young children and adolescents would result in the greatest 
reductions in congenital CMV infections in populations with moderate and high baseline maternal 
seroprevalence. Such a vaccination strategy, assuming 70% vaccine efficacy, 90% coverage and 5-
year duration of protection, could ultimately prevent 30%-50% of congenital CMV infections. At 
equilibrium, this strategy could result in a 30% reduction in congenital CMV infections due to 
primary maternal infection in the United States but a 3% increase in Brazil. The potential for an 
increase in congenital CMV infections due to primary maternal infections in Brazil was not 
predicted with use of a vaccine that confers protection for greater than 5 years.
Interpretation—Modeling suggests that vaccination strategies that include young children will 
result in greater declines in congenital CMV infection than those restricted to adolescents or 
women of reproductive age. Our study highlights the critical need for better understanding of the 
relative contribution of type of maternal infection to congenital CMV infection and disease, the 
main focus of vaccine prevention.
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INTRODUCTION
Congenital cytomegalovirus (cCMV) infection occurs when virus from the mother crosses 
the placenta and infects the immunologically immature fetus, as a result of primary maternal 
infection, reinfection or reactivation. The consequences of cCMV infection include fetal or 
infant death or neurological and sensory impairments [1, 2]. Children with cCMV-related 
disabilities may require extensive medical care, special education services, and 
interventions. Costs associated with cCMV infections in the United States were estimated in 
the 1990’s to be at least $1.9 billion annually [3]. Population-based epidemiological data are 
needed to update and provide more complete estimates of the full spectrum of disease and 
related disabilities caused by cCMV [4]. Because of the burden associated with cCMV 
disease, a CMV vaccine was rated as a “highest priority” for vaccine development by the 
Institute of Medicine in the United States [3, 5]. Several CMV vaccines have been evaluated 
in clinical trials, although none is yet close to licensure [6].
Mathematical modeling has become increasingly useful for investigating the dynamics of 
infection and potential impact of vaccination and identifying critical knowledge gaps for 
study [7]. Identifying which populations to target for CMV vaccination that would result in 
greatest reductions in the burden of cCMV disease may provide additional insight for the 
development and design of future CMV vaccines and clinical trials globally. Understanding 
how vaccination strategies might need to be tailored to underlying population epidemiology 
is important because of substantial differences in CMV seroprevalence and proportion of 
cCMV infections due to primary maternal infection within and between countries. We used 
mathematical modeling to explore the potential impact of CMV vaccination in the United 
States, a population with moderate seroprevalence, and in Brazil, a population with high 
seroprevalence. We estimated the potential impact of vaccination on cCMV infections, 
overall and by type of maternal infection, both at equilibrium and with respect to time after 
vaccine introduction.
METHODS
We constructed a deterministic, age-specific and time-dependent mathematical model of 
pathogen transmission, with six groups in our human population: susceptible, primarily 
infected, latently infected, reactivated/reinfected, susceptible vaccinated (before primary 
infection), and latently infected vaccinated (after primary infection) (Figure 1). The system 
of differential equations describing the model is provided in the supplementary material 
(Appendix 1).
We defined susceptible as CMV seronegative individuals who have not been previously 
infected nor effectively vaccinated. We defined primarily infected as individuals who were 
infectious after first exposure to wild type CMV strain, latently infected as individuals who 
were seropositive from wild type infection but not infectious, and reactivated/reinfected as 
individuals who were infectious during reactivation of the latent virus or after secondary 
exposure to a new CMV strain. We assumed persons vaccinated while susceptible 
(susceptible vaccinated) were protected against primary infection, and persons vaccinated 
while latently infected (latently infected vaccinated) were protected against reactivations or 
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reinfections, and primarily infected or reactivated/reinfected individuals were not effectively 
vaccinated. We assumed an age-specific duration of infectiousness [8], a lower susceptibility 
to reinfections among latently infected individuals [9, 10], and latency duration of 20 years 
[11, 12] (Table 1), although these parameters are not well-understood.
For disease transmission, we used different age group-specific contact mixing matrices (a 
quantitative description of the average number of contacts between individuals per day) to fit 
CMV seroprevalence data. The base-case scenario and estimates are based on the contact 
mixing matrix that best fit the seroprevalence data, a modified version of pattern III of 
Azevedo’s model [11], in which the child-to-adult transmission route was attenuated. This 
pattern includes higher transmission probabilities between young children due to their long 
duration of viral excretion, high viral titers in body fluids [8] and high contact rate, and from 
adults to children, as a result of transmission through breastfeeding [13, 14].
Our models were parameterized using CMV seroprevalence [15, 16] and population-specific 
data from the United States and Brazil (Supplementary material – Table 1). We calculated 
the basic reproduction number (R0), which is the expected number of secondary infections 
arising from a single individual over the course of its infectious period when introduced into 
a susceptible population [17], using two different methods: the ‘next generation matrix’ 
(NGM) method [18], and the ‘constant force of infection’ method [19]. The former allows us 
to calculate R0 exactly for our specific model structure, while the latter is based only on 
seroprevalence data to deduce R0 under the assumption that the force of infection is the 
same for all ages (Supplementary material – Appendix 2).
The number of cCMV infections by type of maternal infection in the pre- and post-
vaccination equilibrium was estimated using age group-specific birth rates among women 
15-49 years-old for each country (Supplementary Material - Table 1) and a 1:1 male-female 
ratio in the population applied to the annual number of individuals with primary infection, 
reinfection and reactivation. The impact of vaccination was estimated as the percent 
reduction in the number of cCMV infections post-vaccination (1 minus the ratio between the 
post- and pre-vaccination annual number of cCMV infections times 100).
We assessed the effect of age at vaccination, effectively vaccinated proportion (vaccine 
coverage times vaccine efficacy), and duration of vaccine protection on cCMV infections, 
overall and by type of maternal infection both at equilibrium and with respect to time since 
vaccine introduction. The schedules considered for vaccine administration were based on 
ages when vaccines are typically recommended to children (0-12 months, 12-18 months, 
10-11 years) or ages of childbearing potential before first pregnancy (15-19 years, and 20-29 
years) [20]. We varied effectively vaccinated proportion from 0 to 100%, with vaccine 
coverage starting at desired coverage levels, and vaccine efficacy based on ‘all-or-nothing’ 
mechanism of vaccine action, i.e. complete protection to a subset of the individuals who are 
given the vaccine but no protection in the other subset [21]. In the model simulations, we 
performed ‘vaccination’ once at each of the schedules, with a proportion ω of the susceptible 
and latently infected moving to their respective effectively vaccinated states very rapidly. We 
varied duration of vaccine protection from 0 to 50 years, after which individuals would 
return to their original susceptible or latently infected states.
Lanzieri et al. Page 3
Vaccine. Author manuscript; available in PMC 2016 April 25.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
We conducted sensitivity analyses to evaluate the model-generated distribution of cCMV 
infections by type of maternal infection in the pre and post-vaccination equilibrium and the 
impact of vaccination. In these analyses, we assumed two different contact mixing matrices, 
pattern I from Azevedo’s study [11], in which the peak of transmission occurs between 
children-children only, and the UK ‘Polymod’ matrix [22]; 5-year latency duration; and a 
scenario in which the vaccine would provide no protection against reactivation or reinfection 
in latently infected individuals. All simulations were conducted using the software package 
Berkeley-Madonna version 8.3.18 (http://www.berkeleymadonna.com).
RESULTS
Ro and estimated distribution of cCMV infections by type of maternal infection in the pre-
vaccine state
Using the NGM method, we estimated an R0 of 1.94 in the United States, and 5.17 in Brazil, 
similar to those estimated using the ‘constant force of infection’ method (Supplementary 
material). Assuming the modified contact mixing matrix pattern III and 20-year latency 
duration, the model-generated distribution of cCMV infections by type of maternal infection 
in a pre-vaccine state was 16% from primary maternal infection, 12% from reinfection and 
72% from reactivation for the United States and 15%, 38% and 47% respectively for Brazil 
(Table 2). In the sensitivity analyses, the proportion of cCMV infections from primary 
maternal infections ranged from 5% to 30% in the United States and from 6% to 15% in 
Brazil (Supplementary material - Table 2). The proportion of cCMV infections from 
maternal reinfections ranged from 3% to 12% in the United States and from 13% to 48% in 
Brazil (Supplementary material - Table 2).
Estimated reductions in CMV seroprevalence after vaccine introduction
Assuming a vaccine with 70% efficacy, 90% coverage, and 5-year duration of protection, the 
greatest reduction in CMV seroprevalence from natural infection would be achieved by 
vaccination at age 0-12 months, potentially leading to CMV elimination both in the United 
States and in Brazil. This was predicted with shorter duration of vaccine protection (i.e. 2.5 
years) as well, due to model assumptions of high infectiousness and contact rates among 
children ≤ 5 years of age. Considering vaccination of persons beginning at age ≥ 12 months, 
assuming the same vaccine parameters above, the greatest reduction of CMV seroprevalence 
would be achieved by a combined schedule of vaccination at ages 12-18 months and 15-19 
years, followed by vaccination at age 12-18 months only, in both the United States and 
Brazil (Figures 2a and 2b). Vaccination at ages 15-19 or 20-29 years would result in limited 
reduction in CMV seroprevalence.
Estimated impact of vaccination on cCMV infections
The greatest reduction in the overall number of cCMV infections would result from 
vaccination at age 0-12 months, potentially leading to elimination of cCMV infection both in 
the United States and in Brazil (Figures 3a and 3b). Considering other childhood vaccination 
strategies, a combined schedule of vaccination at ages 12-18 months and 15-19 years in both 
settings would result in reductions in the overall number of cCMV infections of 
approximately 40% if 50% of individuals were vaccinated and 80% if 100% were 
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vaccinated. Among the other single age groups > 12 months of age considered for 
vaccination, the greatest reductions in the overall number of cCMV infections would result 
from vaccination at age 12-18 months.
Regarding vaccination of adolescents or adults, vaccination at age 20-29 years would result 
in reductions in the overall number of cCMV infections in the United States similar to those 
predicted for vaccination at age 12-18 months, particularly as the effectively vaccinated 
proportion approaches 100%, and greater than those predicted with vaccination of 
adolescents (Figure 3a). In contrast, in Brazil, vaccination targeted at ages 10-11 or 15-19 
years would lead to greater reductions in the overall number of cCMV infections than 
vaccination at age 20-29 years but less than the reductions achievable by childhood 
vaccination (Figure 3b).
Estimated impact of vaccination and duration of vaccine protection on cCMV infections by 
type of maternal infection
The changes in the distribution of cCMV infections by type of maternal infection throughout 
the decades-long period after vaccine introduction leading up to equilibrium are shown in 
Table 2. In the United States, assuming 90% vaccination coverage, 70% vaccine efficacy and 
5-year duration of protection, a combined schedule of vaccination at ages 12-18 months and 
15-19 years would have the greatest reduction at equilibrium as well as at 10, 20 and 50 
years after vaccine introduction. This strategy would lead to a reduction of approximately 
30% in the overall number of cCMV infections 10 years after vaccine introduction, with 
reductions of approximately 50% in the number of those due to primary maternal infection. 
Approximately 50 years after vaccine introduction, there would be approximately 30% 
fewer cCMV infections due to primary maternal infection than pre-vaccination and 
approximately 70% and 45% fewer cCMV infections due to maternal reinfection and 
reactivation, respectively, resulting in a reduction of 45% in the overall number of cCMV 
infections. In the United States, the distribution of cCMV infections by type of maternal 
infection would change in the post-vaccination equilibrium, with a slight increase in the 
proportion of cCMV infections due to primary maternal infection.
In Brazil, ten years after introduction of a combined schedule of vaccination at ages 12-18 
months and 15-19 years, assuming 90% vaccination coverage, 70% vaccine efficacy and 5-
year duration of protection, the overall number of cCMV infections would decrease by 
approximately 50%, with approximately 50%, 65% and 30% reductions in those due to 
maternal primary infection, reinfection and reactivation, respectively (Table 2). However, an 
increase in the number and proportion of cCMV infections due to primary maternal infection 
would occur after 50 years of vaccination. The strategy with the largest potential for an 
increase in the number of cCMV infections due to primary maternal infection was 
vaccination at age 12-18 months only; although the overall number of cCMV infections 
would still be approximately 30% lower than pre-vaccination levels, there would be an 
approximately 25% increase in cCMV infections due to primary maternal infection (Table 
2).
With increases in duration of vaccine protection, vaccination at ages 12-18 months or 15-19 
years in the United States would lead to greater reductions in the number of cCMV 
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infections, overall and due to any type of maternal infection (Figure 4a and 4b). Increased 
duration of vaccine protection would also result in greater reductions in the number of 
overall cCMV infections in Brazil. The potential for an increase in cCMV infections due to 
primary maternal infection in Brazil was predicted for vaccination at age 12-18 months 
when duration of vaccine protection was <20 years (Figure 4c) and, for a combined schedule 
with vaccination at ages 12-18 months and 15-19 years, when duration of protection was <5 
years (Figure 4c). Vaccination at age 15-19 years only in Brazil would not increase cCMV 
infections due to primary maternal infection, regardless of the duration of vaccine protection 
(Figure 4d), but reduction in the overall number of cCMV infections and those due to 
maternal reinfection and reactivation would be lower than with vaccination at age 12-18 
months only or combined with vaccination at age 15-19 years.
Sensitivity analyses
In our sensitivity analyses, the predicted reductions in cCMV infections would not change 
substantially with the assumption of 5-year latency duration instead of 20 years 
(Supplementary material – Table 3, columns a vs. b, and columns c vs. d). Assuming no 
vaccine protection against non-primary infections, the predicted reductions in cCMV 
infections would be smaller with vaccination strategies targeting adolescents or adults 
(Supplementary material – Table 3, columns a vs. c, for example). Assuming different 
contact mixing matrices, vaccination at age 12-18 months only or combined with 
vaccination at age 15-19 years would result in smaller reductions in cCMV infections with 
pattern I from Azevedo’s study, (Supplementary material – Table 3, columns a vs. e), and 
greater reductions with the Polymod matrix (Supplementary material – Table 3, columns a 
vs. g).
DISCUSSION
Using a mathematical model of CMV epidemiology parameterized with data from the 
United States and Brazil, we assessed the potential impact of vaccination on CMV 
seroprevalence and cCMV infections. Concurrent vaccination at ages 12-18 months and 
15-19 years would have the greatest impact on reducing the number of cCMV infections 
overall, both in populations with moderate and high baseline maternal seroprevalence. Our 
model suggests that such a vaccination strategy, assuming a vaccine with 70% efficacy, 90% 
coverage and 5-year duration of protection, could prevent nearly 30%-50% of cCMV 
infections during the 10-50 years after vaccine introduction. Better understanding the 
relative contribution of type of maternal infection to overall burden of cCMV infection and 
cCMV disease, the main focus of vaccine prevention [20, 23], is critical.
Our analyses represent significant progress beyond the work of Griffiths [24] and Azevedo 
[11]. We incorporated type of maternal infection into the model and explored how the 
impact of CMV vaccination might vary by population-specific reproduction numbers and 
baseline seroprevalence. Azevedo found that vaccination at age 2-6 months may increase 
overall cCMV infections if vaccine-induced immunity wanes before 20 years [11]. With 
vaccination at age 12-18 months and vaccine duration of protection <20 years, our model 
predicted a decrease in the overall number of cCMV infections and a potential increase in 
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the number of cCMV infections due to primary maternal infection because of a shift in the 
age of primary infection into childbearing age in Brazil. Because primary maternal 
infections are more likely to result in maternal-to-fetus transmission and appear to be more 
likely to result in cCMV disease than for non-primary infections [10], further investigation 
into the impact that increases in numbers of cCMV infections due to primary maternal 
infection might have on total cCMV disease burden is needed. Our model suggests that this 
potential perverse effect could be ameliorated by a combined vaccination schedule at age 
12-18 months and 15-19 years. We did not predict a perverse effect from CMV vaccination 
in the US-based simulations. However, further investigation into the potential for a perverse 
effect in sub-groups in the US population with a disproportionate burden of CMV infection 
[15, 19] should to be considered in future planning of vaccination strategies.
The proportion of cCMV infections due to maternal reinfection vs. reactivation is not well 
understood, nor is the relative contribution of either of them to cCMV disease [20]. A study 
from Brazil found that nearly half of the mothers who delivered an infant with cCMV 
infection had evidence of infection with more than one CMV strain before or during the 
affected pregnancy and 18% seroconverted to a new strain during the affected pregnancy 
[25]. As such, a vaccine that provides protection to both CMV seronegative and seropositive 
individuals would have the greatest potential for reducing the number of cCMV infections in 
populations with high baseline maternal CMV seroprevalence. Encouraging results from 
studies of the glycoprotein B/MF59 vaccine indicate that not only did it have a 50% efficacy 
against primary CMV infection [26], it was also capable of boosting immunity in CMV-
seropositive women [27, 28].
Our model relies on a number of key assumptions about CMV epidemiology for which data 
are lacking. Specifically, the susceptibility to reinfection and duration of latency and viral 
excretion following non-primary infections are unknown [8, 9, 25]. We did not incorporate 
the risk of maternal-to-fetal transmission of CMV by maternal infection type into our model 
because data are scarce for maternal reinfections or reactivations; as a result, the model may 
have overestimated the contribution of primary infection to cCMV infections. In sensitivity 
analyses, the estimated reductions in cCMV infections were similar when varying latency 
duration from 5 to 20 years. However, they were sensitive to whether the vaccine protects 
seropositive individuals against non-primary infections, when considering vaccination of 
adolescents or young adults, and to the contact mixing matrices used, which derived 
different the distributions of cCMV infections by type of maternal infection.
Although the focus of CMV vaccine trials for prevention of cCMV infection thus far has 
been mainly on prevention of primary infection in seronegative women of childbearing age 
[26], modeling suggests universal vaccination of infants could result in elimination of cCMV 
infection in populations with moderate and high baseline maternal seroprevalence. Such a 
strategy would require a vaccine that would be efficacious in the face of potential 
interference by maternal antibodies and early exposure to CMV as a result of breastfeeding. 
In the absence of vaccination during infancy, modeling suggests that vaccination strategies 
that include young children would result in greater declines in cCMV infection than those 
restricted only to adolescents or women of reproductive age. Designing and conducting 
vaccine trials that include infants or young children will require identification of clinically 
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important and feasible-to-study endpoints that could lead to licensure of a vaccine with the 
purpose of preventing cCMV disease [20]. Future studies of CMV vaccines should evaluate 
effectiveness and duration of protection among young children and adolescents, in 
seronegative and seropositive individuals, and in settings of lower and higher force of 
infection.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Compartmental model of CMV infection with vaccination
Individuals enter susceptible compartment by birth (αN) and may also leave each 
compartment by death (µ(a)). The average time individuals in each age group (a) spend in 
that age group is proportional to the length of the age group (a) (not shown). λ(t,a) is the 
force of infection (primary infection) among susceptible individuals and ελ(t,a) is the force 
of infection (reinfection) among individuals with latent infection; γ and γr indicate the rate at 
which primarily infected develop latency and reactivated/reinfected individuals return to 
latently infected (1/time to recover from primary or non-primary infection), respectively; σ 
is the rate at which individuals reactivate a latent infection (1/time to reactivate CMV 
infection); ω is the effectively vaccinated proportion (vaccine coverage times vaccine 
efficacy); and ϕ is the rate at which individuals lose vaccine protection (1/time to lose 
vaccine protection). Vaccination occurs once in any given scenario, with a proportion ω of 
the susceptible and latently infected moving to their respective effectively vaccinated 
compartments very rapidly. Primarily infected and reactivated/reinfected individuals are not 
effectively vaccinated.
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Figure 2. 
Impact of vaccination on CMV seroprevalence from natural infection by age group at 
equilibrium, assuming different ages at vaccination, age-specific duration of infectiousness, 
20 year duration of latency, and a vaccine with 70% efficacy, 90% coverage and 5-year 
duration of protection, United States and Brazil.
Black dots indicate available CMV serological data; U.S. data are from the 1999-2004 
National Health and Nutrition Examination Survey [15], data for the age group 0-5 years 
were not available; Brazilian data are from CMV serological data from Caieiras, Sao Paulo, 
1990-1991 [16].
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Figure 3. 
Overall reduction in the annual number of cCMV infections at equilibrium by proportion of 
individuals effectively vaccinated by age at vaccination, assuming age-specific duration of 
infectiousness, 20 year duration of latency, and a vaccine with 5-year duration of protection, 
United States and Brazil.
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Figure 4. 
Reduction in the annual number of cCMV infections, by type of maternal infection, at 
equilibrium by duration of vaccine protection, assuming age-specific duration of 
infectiousness, 20 year duration of latency, 90% vaccine coverage, 70% vaccine efficacy, 
and vaccination at 12-18 months or 15-19 years of age, United States and Brazil.
In figure 4c, black lines indicate impact of vaccination at 12-18 months of age only and gray 
lines indicate impact of combined schedule with vaccination at 12-18 months of age and 
15-19 years of age.
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Table 1
Notation, definition and values of parameters in the mathematical model
Notation Definition Value
1/γ Time to recover from primary infection Age-specific:
≤ 5 year-olds: 2 years
6-19 year-olds: 1 year
≥ 20 year-olds: 0.5 year
1/γr Time to recover from non-primary infection (1/ γ)/2
1/σ Time to reactivate CMV infection 20 years or 5 years
ω Effectively vaccinated proportion (vaccine coverage
times vaccine efficacy)
0-100%
1/ϕ Time to lose vaccine protection 2-50 years
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